Lupus and Allied Diseases Association Donates $150,000 to Advance Lupus Research
Our deepest thanks go to the Lupus and Allied Diseases Association, Inc. (LADA) for their extremely generous donation of $150,000 to...
FDA Accepts Application for Gazyva® as Potential Lupus Nephritis Treatment
FDA Accepts Application for Gazyva® as Potential Lupus Nephritis Treatment
Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is eager to share exciting news. The U.S. Food and Drug Administration accepted the supplemental Biologics License Application (sBLA) from Genentech for Gazyva® (obinutuzumab) as a potential treatment of lupus nephritis. This development provides hope for another treatment option for those living with lupus nephritis.
